Please login to the form below

Not currently logged in
Email:
Password:

GSK presents Avandia data To FDA

GSK presents its data on Avandia to an FDA advisory committee in order to stay the agency's proposed market ban of the diabetes treatment

UK pharmaceutical company, GlaxoSmithKline (GSK) has presented its data on Avandia (rosiglitazone) to an FDA advisory committee.

The presentation revealed what GSK said was the weight of scientific evidence available to address a question of increased risk of cardiovascular ischemic events.

The question was raised by different meta-analyses performed by GSK, the FDA and one published in the New England Journal of Medicine (NEJM).

Although a meta-analysis can identify scientific questions for further investigation, such analyses can also have significant limitations. GSK believes a full and scientific evaluation of all the data does not confirm the safety questions originally raised by the FDA and other bodies.

GSK says that longitudinal clinical trials are the most robust tools available to answer questions raised by meta-analyses. A 1997 published review of meta-analyses revealed 33 per cent of the conclusions of meta-analyses are not confirmed by subsequent clinical trials.

The Avandia data included 116 clinical trials in over 52,000 patients. Of these, the ADOPT, DREAM and RECORD studies examine 14,000 patients. RECORD, for example specifically investigates cardiovascular effects in a high cardiovascular-risk population.

The UK's largest pharmaceutical company also presented four other ongoing long-term studies, which is says will increase available data on the cardiovascular safety of Avandia: BARI-2D, ACCORD, VADT and APPROACH.

GSK also says that there is no consistent or systematic evidence that Avandia increases the risk of heart attack or cardiovascular death in comparison to other anti-diabetic medicines.

Senior FDA officials have admitted they do not know if Avandia increases heart-attack risk and are asking the advisory panel if the drug should come off the market or stay with stronger warnings or limits.

30th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics